NCT03146468View on ClinicalTrials.gov

Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation

PHASE2UnknownINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

May 8, 2017

Primary Completion Date

March 1, 2022

Study Completion Date

March 1, 2022

Conditions

Haematological Malignancy

Interventions

DRUG

Nivolumab Injection

Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface receptor

Trial Locations (1)

3050

Royal Melbourne Hospital, Parkville

Sponsors

Lead Sponsor

Melbourne Health

All Listed Sponsors

lead

Melbourne Health

OTHER